A Gendolla

Summary

Affiliation: University of Essen
Country: Germany

Publications

  1. ncbi Clinical profile and practice experience of almotriptan
    A Gendolla
    University Clinic and Policlinic of Essen, Essen, Germany
    Cephalalgia 24:16-23. 2004
  2. ncbi Part I: what do patients really need and want from migraine treatment?
    Astrid Gendolla
    Department of Neurology, University Essen, Germany
    Curr Med Res Opin 21:S3-7. 2005
  3. ncbi Early treatment in migraine: how strong is the current evidence?
    A Gendolla
    Klinik fur Neurologie, Universitätsklinik Essen, Essen, Germany
    Cephalalgia 28:28-35. 2008
  4. ncbi [Treatment and prophylaxis of an acute migraine attack]
    H C Diener
    Universitätsklinik für Neurologie, Essen
    MMW Fortschr Med 146:41, 43-5. 2004
  5. ncbi Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial
    H C Diener
    Department of Neurology and Headache Centre, University Hospital Essen, Essen, Germany
    Cephalalgia 29:921-7. 2009
  6. ncbi The therapeutic profile of zolmitriptan in clinical practice
    H C Diener
    Department of Neurology, University Essen, Essen, Germany
    Int J Clin Pract 58:795-800. 2004
  7. ncbi Migraines with and without aura and their response to preventive therapy with topiramate
    U Reuter
    Department of Neurology, Charite Universitatsmedizin, Berlin, Germany
    Cephalalgia 30:543-51. 2010
  8. ncbi Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a post-marketing surveillance study in Germany
    Hans Christoph Diener
    Department of Neurology, University Essen, Germany
    Curr Med Res Opin 21:S18-24. 2005
  9. ncbi Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial
    Hans Christoph Diener
    Department of Neurology, University Essen, Germany
    Eur Neurol 53:41-8. 2005
  10. ncbi Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey--phase IV
    E Anne MacGregor
    City of London Migraine Clinic, London, UK
    Curr Med Res Opin 20:1777-83. 2004

Collaborators

Detail Information

Publications11

  1. ncbi Clinical profile and practice experience of almotriptan
    A Gendolla
    University Clinic and Policlinic of Essen, Essen, Germany
    Cephalalgia 24:16-23. 2004
    ..Almotriptan therapy is associated with a low incidence of adverse events, including those affecting the central nervous system and chest...
  2. ncbi Part I: what do patients really need and want from migraine treatment?
    Astrid Gendolla
    Department of Neurology, University Essen, Germany
    Curr Med Res Opin 21:S3-7. 2005
    ....
  3. ncbi Early treatment in migraine: how strong is the current evidence?
    A Gendolla
    Klinik fur Neurologie, Universitätsklinik Essen, Essen, Germany
    Cephalalgia 28:28-35. 2008
    ..Ultimately, migraine treatment strategies require optimization in order to meet patient expectations and to reduce the current burden of migraine-associated disability...
  4. ncbi [Treatment and prophylaxis of an acute migraine attack]
    H C Diener
    Universitätsklinik für Neurologie, Essen
    MMW Fortschr Med 146:41, 43-5. 2004
    ..Through nonmedicinal and medicinal prophylactic measures, the frequency and intensity of the migraine attacks can be reduced. Keeping a headache diary for documentation is essential...
  5. ncbi Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial
    H C Diener
    Department of Neurology and Headache Centre, University Hospital Essen, Essen, Germany
    Cephalalgia 29:921-7. 2009
    ..03), and a borderline significant difference in responders (40% vs. 25%, P = 0.07). The incidence of adverse events was similar between treatments. This study indicates that telmisartan might be effective in migraine prophylaxis...
  6. ncbi The therapeutic profile of zolmitriptan in clinical practice
    H C Diener
    Department of Neurology, University Essen, Essen, Germany
    Int J Clin Pract 58:795-800. 2004
    ..5 mg dose of zolmitriptan in clinical practice in migraine. Zolmitriptan was very well tolerated, with patients expressing a distinct preference for zolmitriptan over previous treatments...
  7. ncbi Migraines with and without aura and their response to preventive therapy with topiramate
    U Reuter
    Department of Neurology, Charite Universitatsmedizin, Berlin, Germany
    Cephalalgia 30:543-51. 2010
    ..Similarly, there were no statistically significant changes in number of auras between groups. Thus, topiramate appears to reduce migraine auras in parallel with headache reductions, which are similar in patients with and without aura...
  8. ncbi Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a post-marketing surveillance study in Germany
    Hans Christoph Diener
    Department of Neurology, University Essen, Germany
    Curr Med Res Opin 21:S18-24. 2005
    ....
  9. ncbi Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial
    Hans Christoph Diener
    Department of Neurology, University Essen, Germany
    Eur Neurol 53:41-8. 2005
    ..To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg...
  10. ncbi Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey--phase IV
    E Anne MacGregor
    City of London Migraine Clinic, London, UK
    Curr Med Res Opin 20:1777-83. 2004
    ..To determine which medications UK migraineurs have access to and assess the usage of these products in a 'real-life' setting...
  11. ncbi Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial
    Hans-Christoph Diener
    Department of Neurology, University Essen and Bayer Healthcare, Essen, Germany
    Headache 45:874-82. 2005
    ..77). CONCLUSIONS: Almotriptan 12.5 mg is an effective and well-tolerated alternative for patients who respond poorly to sumatriptan 50 mg. A poor response to one triptan does not predict a poor response to other agents in that class...